A specialist in computational biology, AI/ML, digital health, biosensors, and advanced analytics, he is known for bringing scientific depth together with product‑driven technology leadership. His work focuses on building modern research platforms, enabling multimodal data integration, and translating cutting‑edge computational methods into real impact for GSK’s discovery and translational programs. Anthony’s leadership reflects more than two decades of experience at the intersection of computing, life sciences, and large‑scale digital transformation.

Before joining GSK, Anthony spent over 14 years at Johnson & Johnson Innovative Medicine, rising to Vice President and Head of Technology for Research Systems, where he oversaw digital strategy and technology enablement for discovery, early development, and clinical supply. His earlier roles included leading global scientific information systems, data science initiatives, and AI‑driven research capabilities.

Anthony also serves on the Board of Directors of the Pistoia Alliance and previously contributed to Nature’s Scientific Data advisory panel, underscoring his commitment to open science and data standards. He holds both an MSc in Advanced Computing and a PhD in Computing from Imperial College London, where he specialized in artificial intelligence and computational methods.

Dr. Sandler provided leadership and technical expertise for Research & Development computing in the pharmaceutical industry. Most recently, he led teams to provide information technology support at several Pfizer Global research and development sites in the United States and the United Kingdom.

Dr. Sandler received his PhD in Physics and Astronomy in July of 1977 from the University of Missouri-Columbia.

Mike is a seasoned leader with a deep understanding of how technology adds value across the drug development life cycle and a strong track record of building cross-functional teams to deliver strategic capabilities across complex ecosystems. He is currently responsible for driving the strategic partnership between IT and Global Development Operations at Bristol Myers Squibb.

Mike earned his MBA from Northeastern University with a dual concentration in High Technology and Innovations Entrepreneurship and a Bachelor of Science in Information Systems Analysis & Development from Drexel University.

Miguel Teodoro, PhD, MS, is the global Head of IT Research, Translational Medicine, and Clinical Pharmacology at Boehringer Ingelheim. In this role, he defines and drives the global IT strategy for pharmaceutical research, aligning R&D priorities with digital, data, and analytics capabilities to measurably accelerate scientific decision‑making across the R&D value chain.

Miguel has more than two decades of experience at the intersection of life sciences and information technology. Since joining Boehringer Ingelheim, he has held a series of senior leadership positions within R&D IT, spanning discovery informatics, high‑performance computing, research platforms, and architecture. His work has focused on building scalable, sustainable digital platforms and data foundations that accelerate scientific innovation while ensuring robust governance and compliance in a global research environment.

He holds a PhD in Biochemistry and Computational Chemistry and an MS in Computer Science from Rice University, as well as a degree in Applied Chemistry/Biotechnology from Universidade Nova de Lisboa. This interdisciplinary background enables him to bridge scientific and technological perspectives and to lead multidisciplinary teams delivering advanced digital capabilities for R&D organizations.

As a member of the PRISME Forum Board of Directors, Miguel is committed to advancing pre‑competitive collaboration, sharing best practices, shaping industry approaches to R&D IT strategy, and adopting new technologies across the global biopharmaceutical community.